Background. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are two drug classes with well-documented renal protective effects. However, whether there is any difference among individual drugs remains unknown. In this study, we aimed to compare the efficacy of individual ACEIs/ARBs on major renal outcomes in adults with diabetic kidney disease (DKD). Methods. We conducted a Bayesian-framework network metaanalysis with a random effects model. We searched PubMed, Embase, Scopus, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov for clinical trials of ACEIs or ARBs as monotherapy compared with other conventional antihypertensive drugs or placebo. Primary outcomes were end-stage renal disease (ESRD) and albuminuria/proteinuria (including change in albuminuria/proteinuria, progression to macroalbuminuria and remission to normoalbuminuria). Secondary outcome was doubling of serum creatinine levels. We also assessed for hyperkalemia, cough and angioedema/edema. International prospective register of systematic reviews (PROSPERO) registration CRD42016036997. Results. A total of 100 studies with data for 22 365 DKD patients, the majority of whom had type 2 diabetes, were included. Individual ACEIs and ARBs at goal doses showed no significant differences in ESRD and doubling of serum creatinine levels. They also shared similar effects on albuminuria/proteinuria reduction and progression or remission of albuminuria. When combining three outcomes of albuminuria/proteinuria as a single endpoint, most ACEIs/ARBs consistently showed favorable antiproteinuric effect, with little difference in the possibility of being the superior treatment for improving albuminuria/ proteinuria. Primary outcomes did not change substantially in meta-regressions and sensitivity analyses. Findings were limited by lack of dose equivalence and paucity of data for some outcomes.
A B S T R A C T
Background. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are two drug classes with well-documented renal protective effects. However, whether there is any difference among individual drugs remains unknown. In this study, we aimed to compare the efficacy of individual ACEIs/ARBs on major renal outcomes in adults with diabetic kidney disease (DKD). Methods. We conducted a Bayesian-framework network metaanalysis with a random effects model. We searched PubMed, Embase, Scopus, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov for clinical trials of ACEIs or ARBs as monotherapy compared with other conventional antihypertensive drugs or placebo. Primary outcomes were end-stage renal disease (ESRD) and albuminuria/proteinuria (including change in albuminuria/proteinuria, progression to macroalbuminuria and remission to normoalbuminuria). Secondary outcome was doubling of serum creatinine levels. We also assessed for hyperkalemia, cough and angioedema/edema. International prospective register of systematic reviews (PROSPERO) registration CRD42016036997. Results. A total of 100 studies with data for 22 365 DKD patients, the majority of whom had type 2 diabetes, were included. Individual ACEIs and ARBs at goal doses showed no significant differences in ESRD and doubling of serum creatinine levels. They also shared similar effects on albuminuria/proteinuria reduction and progression or remission of albuminuria. When combining three outcomes of albuminuria/proteinuria as a single endpoint, most ACEIs/ARBs consistently showed favorable antiproteinuric effect, with little difference in the possibility of being the superior treatment for improving albuminuria/ proteinuria. Primary outcomes did not change substantially in meta-regressions and sensitivity analyses. Findings were limited by lack of dose equivalence and paucity of data for some outcomes.
Conclusions. Based on the available evidence, individual ACEIs and ARBs at goal doses appeared to have no or little differences in their effect on major renal outcomes.
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I N T R O D U C T I O N
Diabetic kidney disease (DKD) is a critical and dangerous complication of diabetes, which globally affects 3-4% of adults [1] . Despite rigorous control of hyperglycemia and hypertension, at least one-third of DKD patients still progress to end-stage renal disease (ESRD), a life-threatening complication [2] that requires long-term dialysis or transplantation [3] . Health-care costs related to ESRD treatment are considerable. Blockade of the renin-angiotensin system (RAS) with angiotensinconverting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) to slow the progression of kidney disease is an effective strategy endorsed by current recommendations [4] . Both ACEIs and ARBs inhibit the effects of angiotensin II and, in most cases, are used interchangeably and considered to be equally effective in DKD [5] . However, it is not obvious that individual drugs from the same class are always equivalent [6] , and in fact, they can differ in their mechanisms of action and intrinsic molecular properties. Can these differences be translated into efficacy differences, and is there any single drug that confers superior renoprotection? These questions have been examined in some head-to-head comparison trials, but results are mixed [7] [8] [9] . Several systematic reviews and meta-analyses have compared the renal protective effect between ACEIs and ARBs, although they did not focus on DKD [10, 11] and assessed in terms of drug class effects only, and thus did not determine the efficacy profile for individual drugs [5, [12] [13] [14] [15] . Since traditional meta-analyses have not proved conclusive in resolving these questions, we therefore conducted this network meta-analysis (NMA) by pooling direct (ACEIs versus ARBs) and indirect comparisons (ACEIs/ARBs versus control/placebo) to comparatively assess the efficacy of individual ACEIs/ ARBs on major renal outcomes.
M A T E R I A L S A N D M E T H O D S
Protocol
The pre-specified protocol of this study was registered in the international prospective register of systematic reviews (PROSPERO), CRD42016036997 trial (http://www.crd.york.ac. uk/prospero/display_record.php?RecordID=36997). We performed this NMA in accordance with guidelines by the Cochrane Collaboration [16] and the Agency for Healthcare Research and Quality [17] , and reported our findings according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines [18] . [19, 20] and ClinicalTrials.gov (available at: http:// www.clinicaltrials.gov) to identify reports of relevant randomized controlled trials (RCTs) published up to March 2016, with no language restriction imposed. Additional search sources also included relevant meta-analyses, reviews and websites. The generic names and Medical Subject Headings of 'ACEIs' and 'ARBs' combined with 'DKD' were selected as keywords. For details on the search strategy, see Supplementary data, Table S1 .
Data sources and searches
Selection criteria
The study included adults aged 18 years or older with diabetes who fulfilled the Kidney Disease: Improving Global Outcomes [21] criteria for chronic kidney disease. We excluded participants with normoalbuminuria [albumin-to-creatinine ratio (ACR) <30 mg/g] and those who underwent dialysis or transplantation. If a trial included a proportion of normoalbuminuric patients, only subgroup data on microalbuminuria (ACR 30-300 mg/g) or macroalbuminuria (ACR !300 mg/g) were extracted.
Active drugs included all candidate ACEIs and ARBs, used as monotherapies, compared with each other or with a control (other conventional antihypertensive regimens) or placebo. We included trials that used all drug doses due to a lack of evidence about renal equivalent doses for individual ACEIs/ARBs and based on the rationale that nephropathy patients might require lower drug doses. Standard analyses for each outcome were based on goal doses. In addition, sensitivity analyses were performed for primary outcomes according to doses. We excluded trials that compared ACEIs/ARBs with direct renin inhibitors or lifestyle changes. We also excluded crossover and add-on treatment trials and trials with a study population of <10 participants per group. Moreover, since there is evidence that non-dihydropyridine calcium channel blockers and newer vasodilating beta-blockers have renoprotective effects or reduce proteinuria, independent of their antihypertensive effect [22, 23] , we therefore removed study arms that included these drugs to avoid baseline risk.
The primary outcomes were ESRD and albuminuria/proteinuria, with the latter as three separate outcomes:
(i) change in albuminuria/proteinuria from baseline (continuous data were extracted from 6 months to 4 years during the follow-up period, and whenever possible, data at time points closest to 2 years over 0.5-4 years were used); (ii) progression to macroalbuminuria; and (iii) remission to normoalbuminuria.
The above outcomes were analyzed separately and then combined as a single endpoint. For dichotomous data, we used intention-to-treat datasets, whenever possible. The secondary outcome was doubling of serum creatinine levels. We also assessed for drug-associated adverse events, including hyperkalemia, cough and angioedema/edema.
Data extraction and quality assessment
Data on participants' baseline characteristics, interventions, follow-up duration and outcomes were extracted using data extraction forms. Emails were sent to lead authors at least twice, with requests for further information, if needed. Risk of bias was appraised using standard criteria [16] . For non-English language articles, we translated the abstracts and tables/figures where these provided useful information for our analyses.
Transformations for continuous outcome data
Baseline and follow-up albuminuria/proteinuria values were log-transformed to approximate normal distribution before analysis. For details on specific transformation methods, see Supplementary data, Text S1. Change in albuminuria (urinary albumin excretion rate (AER) or ACR) or proteinuria (urinary protein excretion rate, PER) from baseline to followup in each group was calculated as: DAER change ¼ Log e (AER endpoint ) À Log e (AER baseline ) ¼ Log e (AER endpoint / AER baseline ). The corresponding SD change for DAER change caused by each group is calculated from SD
where c is the correlation coefficient expressing the similarity between baseline and endpoint measurements [16] . We calculated c from the included studies [24] using individual patient data and used the mean of c (c mean ¼ 0.7) for all included studies. Since an estimated value of 0.5 for c was previously reported [25] , c ¼ 0.5 was considered in sensitivity analyses. Missing SD change was estimated using the mean SD change from other included trials [26] . Treatment effects of ACEIs or ARBs, compared with placebo, can be summarized as: [Log e (treatment) À Log e (placebo)] ¼ DAER treatment.change À DAER placebo.change .
NMA and heterogeneity measurement
We used WinBUGS version 1.4.3 (Medical Research Council Biostatistics Unit, Cambridge, United Kingdom, and Imperial College London, London, United Kingdom) to perform the NMA and applied a random effects model within a Bayesian framework Efficacy of ACEIs and ARBs in DKD [27, 28] . Curative effects of ACEIs/ARBs were evaluated by comparing with effects of the placebo. To calculate effect sizes, we used weighted mean differences (WMDs) for continuous data and odds ratios (ORs) for binary data. Geometries of treatment networks were created for each outcome, according to the methods described by Chaimani et al. [29] . We applied the Markov Chain Monte Carlo method and assumed vague prior distribution (0, 10 000) for the means, and uniform prior distribution (0, 5) for between-study standard deviations [30] . For each model containing three sets, we generated 150 000 simulations for each set with different initial values, and discarded the first 50 000 simulations as burn-in. The convergent achievement was measured using the Brooks-Gelman-Rubin plots [31] . The median and 2.5th and 97.5th percentiles of the posterior distribution were reported, based on 100 000 simulations.
Heterogeneity for NMA was measured as between-study variance (V bs ) and divided into three levels-low, moderate and high, as suggested by Barth et al. [32] . Inconsistency or discrepancy between direct and indirect evidence was identified by a parameter inconsistency factor with 95% confidence interval (CI) excluding zero [33] . Conventional pairwise meta-analyses based on the random effects model, as applied by DerSimonian and Laird [34] , were also conducted using Stata 12 (StataCorp LP, Texas, USA)) for comparison with NMA results and further assessment of the network consistency [30] . To rank the curative effect of each drug, we calculated the surface under the cumulative ranking curve (SUCRA), a probability ranging from 0 to 1, with a higher value representing greater effectiveness in terms of the beneficial effect [35] . Inconsistency checking and SUCRA were carried out using R software version 2.15.3 (R Foundation for Statistical Computing, Vienna, Austria). Finally, we appraised the overall model fit [36] and assessed for small-study effects and publication bias [29, 37] .
Meta-regressions and sensitivity analyses were carried out to investigate for potential sources of heterogeneity. In the meta-regression model [28] , both subgroup indicator covariates, including the extent of baseline albuminuria (macro-or microalbuminuria), blood pressure status (hypertension or normotension) and type of diabetes [type 2 diabetes mellitus (DM) or type 1 DM], and continuous covariates, including baseline albuminuria/proteinuria, age, follow-up duration and baseline HbA1c, were considered as potential effect modifiers. Sensitivity analyses were performed for change in albuminuria/proteinuria by: (i) comparing drugs at conventional doses, which were assumed to be twice the drug's defined daily dose (or titrated to twice the defined daily dose)-a drug dose system established by the World Health Organization [38] , (ii) including studies with all doses and (iii) assuming the correlation coefficient c ¼ 0.5.
R E S U L T S
Study characteristics
A total of 100 studies (112 reports) published up to March 2016, comprising a total of 22 365 participants, were included (see the PRISMA flow diagram shown in Figure 1 ) . Of these, 94 studies, comprising a total of 22 080 participants, included drugs at goal doses. The median study duration was 18 months (range: 6-96 months). The mean age of participants was 52 years. There were 84 two-armed trials, and the remaining 10 were multiarmed. Two studies had abstracts available (Hansen 1994, Agardh 1996, see reference [107] and [56] in Supplementary Table S2) . We contacted trial authors for additional information or full texts and successfully received four replies (marked in Supplementary data, Table S2 ), which provided valid information contributing to this study. Clinical characteristics of the included RCTs are shown in Supplementary data, Table S2 . Results of risk of bias assessment and the PRISMA NMA checklist are provided in Supplementary data, Figure S1 and Supplementary data, Table S4 , respectively.
ESRD
ESRD was reported in 861 of 11 625 patients from a total of 16 studies. Network geometry is displayed in Figure 2 . As shown, there were nine oral RAS inhibitors presented in the treatment network. Results for this outcome were ambiguous due to paucity of data. All drugs showed higher probabilities of being superior, compared with the control and placebo (Table 1) . ORs ranged from 0.36 (95% CI 0.05-2.70) for telmisartan to 1.08 (95% CI 0.11-12.95) for enalapril, compared with placebo, with no differences among various comparisons of ACEIs/ARBs.
Change in albuminuria/proteinuria
A total of 86 studies contributed to this outcome assessment, of which 57 reported albuminuria/proteinuria values as medians or geometry means and 29 reported as arithmetic means. A total of 51 studies enrolled patients with microalbuminuria, 21 studies enrolled patients with macroalbuminuria and the remaining 14 enrolled mixed populations. Twenty studies included patients with type 1 DM, 57 studies included patients with type 2 DM and the remaining nine studies included a mix of type 1 and type 2 DM patients or patients with DM of unspecified type. In 47 trials, subjects were hypertensive at baseline. There were 14 505 DKD patients randomized to one of 18 RAS inhibitors or comparators, providing 115 direct comparisons on 190 data points. The most frequent comparisons were between enalapril/lisinopril and a control, and between enalapril/captopril and placebo (Figure 2 ). After adjusting for baseline albuminuria/proteinuria, 13 ACEIs/ ARBs showed superior improvement in albuminuria/proteinuria over placebo, whereas five other ACEIs/ARBs did not achieve statistical significance (Supplementary data, Table S3a ). The ranks indicated by SUCRAs and the point estimates for all drugs were Table S3a ).
Progression to macroalbuminuria
Results, as expected, favoured active drugs over placebo and control. Several drugs, especially valsartan, candesartan and perindopril, showed a significant decrease in progression from microalbuminuria to macroalbuminuria (Supplementary data, Table S3b ). However, individual active drugs demonstrated no differences between each other, except for some comparisons involving ramipril.
Remission to normoalbuminuria
Remission from microalbuminuria/macroalbuminuria to normoalbuminuria was reported in 26 trials, with a total of 4630 participants offering information on 1038 events. NMA showed that telmisartan, valsartan, lisinopril and enalapril were associated with a significant improvement in remission of albuminuria, compared with placebo. However, individual ACEIs/ ARBs failed to show significant differences (Supplementary data, Table S3c ).
When combining the three outcomes of albuminuria/proteinuria as a single endpoint, the majority of ACEIs/ARBs consistently showed favorable antiproteinuric effect, with little difference in treatment superiority possibilities (SUCRAs) in terms of improving albuminuria/proteinuria (Figure 3 ).
Doubling of serum creatinine levels
Data on doubling of serum creatinine levels were obtained from 13 studies with a total number of 11 496 participants. Findings for this outcome were also ambiguous due to the low study numbers. In general, no significant differences were found among various treatment comparisons (Table 2) .
Drug-related toxicity
Effect estimates for angioedema/edema (from 13 studies comprising 7166 participants) were not significant. No drug was found to significantly increase the risk of hyperkalemia (from 12 studies comprising 6152 participants). A total of 10 440 participants from 36 studies reported cough, and ACEIs were frequently found to be associated with cough, compared with ARBs, placebo and control (Supplementary data, Table S3d ).
Heterogeneity and inconsistency
Results of conventional pairwise meta-analyses and Bayesian NMA for the primary outcomes are shown in Supplementary data, Table S5 . Although the point estimates showed some slight differences, the 95% CIs for both types of estimates overlapped in general. Overall, the between-study heterogeneities were low to moderate for primary outcomes. No inconsistent triangular loops were observed in all treatment networks of primary outcomes, except for remission to normoalbuminuria, which showed high heterogeneity, and one out of six loops was inconsistent (Supplementary data, Figure S2 ). The model fit was satisfactory, and no major trend towards small-study effects and publication bias could be found (Supplementary data, Figures S3 and S4 ).
Meta-regression and sensitivity analyses
In network meta-regression analyses with subgroup indicator covariates, the extent of baseline albuminuria, blood pressure status and type of diabetes were not identified as effect modifiers on ESRD. None of the continuous covariates showed influence on treatment effects on primary outcomes, except the mean age of participants, which was borderline significant as an effect modifier on change in albuminuria/proteinuria (regression coefficient ¼ 0.011, 95% CI 0.001-0.021; Supplementary data, Table S7 ). Additionally, after adjusting for these continuous covariates, observed WMDs or ORs for most drugs did not change significantly on major renal outcomes (Supplementary data, Table S6 ). Sensitivity analyses, by including trials using all doses, comparing drugs at their conventional doses, or setting the correlation coefficient c ¼ 0.5, also did not substantially affect the point estimates of change in albuminuria/ proteinuria.
D I S C U S S I O N
Key findings
Head-to-head studies evaluating the relative renal protective effect of ACEIs and ARBs are still limited in number [39, 40] . Most systematic reviews and meta-analyses in this field have been conducted based on drug class only. The comparative efficacy of individual ACEIs/ARBs in slowing the progression of DKD is unclear. Our analysis addressed this question and found that individual ACEIs/ARBs had no or little difference between each other but outperformed conventional therapies and placebo on ESRD and doubling of serum creatinine levels. Additionally, individual ACEIs/ARBs also shared similar effects on albuminuria/proteinuria, progression to macroalbuminuria Efficacy of ACEIs and ARBs in DKD or remission to normoalbuminuria. When pooling all albuminuria/proteinuria outcomes as a single endpoint, most ACEIs/ ARBs consistently showed favorable effects in improving albuminuria/proteinuria. To our knowledge, this is the first analysis of the existing data to directly compare various individual ACEIs/ARBs in terms of renoprotection.
Clinical inferences
Based on the currently limited evidence, our findings are consistent with the viewpoint that individual ACEIs/ARBs may share similar renoprotective effects for DKD patients, as we failed to find important differences among them on major renal outcomes, especially on ESRD and doubling of serum creatinine levels. Although statistical differences were detected for a few treatment comparisons in albuminuria/proteinuria, we should point out that our study findings were limited by the paucity of data for some treatments, and dose equivalence was not taken into full consideration. Moreover, albuminuria/proteinuria is only a surrogate renal outcome. Although multiple studies indicate that albuminuria/proteinuria reduction is associated with protection of renal function [41] , the relationship between albuminuria/proteinuria and hard clinical endpoints such as ESRD still needs to be confirmed by further studies. Hence, the results should be interpreted cautiously and in conjunction with direct-comparison studies. Moreover, achieving maximal renal protection is dependent on many factors. Therefore, when choosing initial drugs, clinicians should consider issues such as the balance between drug-associated benefits and risks, and tolerability, as well as economic assessments.
Comparison with existing literature
The specific renoprotective effect of ACEIs and ARBs as two drug classes has been evaluated by many other review groups, but conclusions drawn from these have not been entirely consistent. Earlier conventional meta-analyses demonstrated that renal profiles of ACEIs and ARBs were not significantly different as drug classes [5, 42, 43] . In an earlier NMA, Vejakama et al. [44] reported a consistent renoprotective effect of ACEIs/ARBs, compared with other antihypertensive agents, in type 2 DM. A recent NMA (157 studies, 43 256 participants) by Palmer et al. demonstrated that ACEIs and ARBs were the most effective strategies against ESRD, compared with placebo and other blood pressure-lowering agents, for DKD patients [12] . Another recent NMA found that ACEIs and ARBs showed similar effects on major renal outcomes in diabetic patients [45] . By contrast, in an NMA by Wu et al., the protective effects of ACEIs versus ARBs did not reach statistical significance, but ACEIs showed higher probabilities of being superior in all outcomes (all-cause mortality, ESRD and doubling of serum creatinine levels), thus lending support to the use of ACEIs as the first-line antihypertensive agent in diabetes [13] . Similarly, another NMA of 119 trials (64 768 patients) focusing on chronic kidney disease also found that ACEIs ranked higher in all-cause mortality outcome and might be superior to ARBs in preventing kidney failure [15] . Disagreements among these findings might be due to different inclusion criteria and study populations. The main difference from our study was that we examined such effect at an individual drug level. Even so, some of our detailed Drugs are displayed according to the SUCRA ranks of efficacy on doubling of serum creatinine levels. Treatment comparisons should be read from left to right, and the values in each cell represent the ORs and 95% CI for the comparison between the column-defining drug and the row-defining drug. ORs <1 favor the column-defining drug (lower incidence of increased creatinine levels). Reciprocals should be taken to get ORs for comparisons in the opposite direction.
study results were consistent with other research studies. For example, we found that telmisartan frequently showed higher probabilities of being superior in decreasing albuminuria/ proteinuria. Similarly, a conventional meta-analysis conducted by Takagi et al. and the All-Literature Investigation of Cardiovascular Evidence (ALICE) group showed that the percentage changes of AER/ACR/PER/urinary protein to creatinine ratio (PCR) for telmisartan, relative to ACEIs, other ARBs and placebo, were À14.08, À19.99 and À39.82%, respectively [25] , indicating that telmisartan was likely effective in the improvement of proteinuria/albuminuria. We also found that the three top-ranked drugs in preventing the doubling of serum creatinine levels were ACEIs (enalapril, lisinopril and captopril). Such finding was partly consistent with a drug class-based NMA showing that only ACEIs significantly reduced the doubling of serum creatinine levels [13] .
Strengths
The strengths of our study include the systematic search, understandability of the analyses and reliability of the results. We structured the network by taking full account of intercommunity and comprehensiveness. We also included both published and unpublished (e.g. abstracts or meeting proceedings) studies to minimize the possibility of publication bias. Additional data required for this work were sought from trial authors and experts in this field. Results of primary outcomes were robust against meta-regressions and sensitivity analyses, from which many clinical parameters were examined with almost none of the parameters identified as effect modifiers.
Limitations
Our study has limitations. First, an NMA not only assumes the included studies are drawn from the same population but also makes a transitivity assumption that, across all pairwise comparisons in the network, no imbalance exists in the distribution of potential effect modifiers [46] . There would be no obvious inconsistency between direct and indirect evidence when such a transitivity assumption is held [47] . In this NMA, heterogeneity was low and inconsistent loops were found only in a few cases, suggesting a proper base for the NMA assumptions. Second, there were very few trials reporting outcomes of ESRD and doubling of serum creatinine levels, thus limiting the conclusiveness of our findings on these endpoints. True differences in comparative efficacy of drugs can only be established by adequate and compelling head-to-head trials, which unfortunately have not been conducted to date. Third, based on large-scale RCTs, current recommendations are in favor of ACEIs for type 1 DM and ARBs for type 2 DM. Trials evaluating ARBs in type 1 DM have been positive, but are still few in number. Further studies of this kind are required to clarify how such choice preferences may influence our findings. Fourth, both ACEIs and ARBs have been shown to have a dose-response relationship in influencing renal parameters [48, 49] . However, to date, a system of equivalent dosing for ACEIs and ARBs has not yet been established and it is difficult to do so. Although drug dose has been considered as a potential effect modifier and taken into account in sensitivity analyses, not all the outcomes were corrected for drug doses. Our analysis regarding this may thus be criticized. These study limitations and specific situations should be considered when applying the results from our metaanalysis. Our findings cannot be extended to diabetic patients without signs of kidney disease, underaged patients and patients with non-DKD, all of whom were excluded from our study to strengthen the homogeneity, as required for an NMA.
In conclusion, individual ACEIs/ARBs failed to show any differences between drugs with respect to preventing the progression of renal failure in DKD. Interpretation of our work supports the notion that different ACEIs/ARBs have comparable benefits on the kidney under diabetic condition. Further head-to-head comparison studies of ACEIs and ARBs as well as studies on ARBs in type 1 DM patients would be helpful to corroborate our findings.
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